• Captopril: ACE Inhibitor Benchmarks and Translational Insigh

  2026-06-05

  Captopril is a well-characterized ACE inhibitor with an IC50 of 6 nM, validated for antihypertensive and anticancer research. Its precise mechanism, high purity, and robust solubility profile support reproducible results in cardiovascular and translational oncology workflows.

• Pioglitazone: PPARγ Agonist Workflows for Inflammatory and M

  2026-06-05

  Pioglitazone, a selective PPARγ agonist from APExBIO, enables researchers to dissect insulin resistance, modulate macrophage polarization, and protect against inflammation in complex disease models. This guide translates recent mechanistic breakthroughs into actionable protocols and troubleshooting strategies for metabolic and immune modulation research.

• HDAC6-Driven α-Tubulin Lactylation Links Metabolism to Micro

  2026-06-04

  This study identifies HDAC6 as a principal enzyme catalyzing reversible lactylation of α-tubulin at lysine 40, revealing a novel metabolic regulation of microtubule dynamics. These findings provide new mechanistic insight into how cellular lactate influences cytoskeletal behavior, with implications for neurobiology and cell cycle research.

• Bestatin (Ubenimex): Precision in Aminopeptidase Assays & MD

  2026-06-04

  Bestatin (Ubenimex) delivers unrivaled specificity for dissecting aminopeptidase-mediated pathways, enabling researchers to decode multidrug resistance and apoptosis mechanisms in cancer models. Practical guidance on experimental workflows, troubleshooting, and advanced applications positions this APExBIO reagent as a cornerstone for protease and MDR research.

• Morin (2-(2,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4

  2026-06-03

  Explore how Morin, a natural flavonoid, uniquely modulates podocyte mitochondrial function through AMPD inhibition. This in-depth article reveals mechanistic insights and practical assay considerations that set Morin apart in diabetes and kidney research.

• UBE2F-SAG–Mediated RHEB Neddylation Drives mTORC1 in Liver C

  2026-06-03

  This study reveals that RHEB is directly neddylated by the UBE2F-SAG axis, a modification that enhances mTORC1 activity and promotes liver tumorigenesis. By delineating this non-cullin substrate pathway, the paper identifies new intervention targets for hepatocellular carcinoma and provides a foundation for mechanistic studies of post-translational modifications.

• Pepstatin A: Applied Aspartic Protease Inhibitor Workflows

  2026-06-02

  Pepstatin A enables precise, reproducible inhibition of aspartic proteases for studies in viral protein processing, osteoclast differentiation, and endothelial dysfunction. This article decodes advanced protocols, troubleshooting, and insights inspired by the latest mechanistic research and APExBIO’s ultra-pure formulation.

• Carvacrol (5-Isopropyl-2-Methylphenol): Advanced Redox Pathw

  2026-06-02

  Explore the multifaceted role of Carvacrol (5-isopropyl-2-methylphenol) in modulating redox signaling, cell cycle arrest, and TRP channel dynamics. This article uniquely bridges mechanistic insights with practical assay guidance for researchers seeking depth beyond standard protocols.

• Rotigotine Hydrochloride: Dopamine D2/D3 Receptor Agonist in

  2026-06-01

  Rotigotine hydrochloride stands out as a versatile dopamine D2/D3 receptor agonist, offering reproducible neuroprotection and robust modeling of Parkinson’s disease and related disorders. This article delivers practical workflows, advanced troubleshooting, and insights from recent research to empower experimental success with APExBIO’s Rotigotine hydrochloride.

• SIS3 Smad3 Inhibitor: Precision Targeting in Fibrosis Resear

  2026-06-01

  SIS3, a highly selective Smad3 inhibitor from APExBIO, empowers researchers to dissect and modulate the TGF-β signaling pathway with unparalleled specificity. This article reveals optimized protocols, troubleshooting insights, and translational applications of SIS3 in fibrosis and cancer models, grounded in the latest mechanistic findings.

• Vancomycin Hydrochloride: Glycopeptide Antibacterial Agent i

  2026-05-31

  Vancomycin hydrochloride stands as a gold-standard glycopeptide antibacterial agent for dissecting Gram-positive bacterial resistance and benchmarking susceptibility workflows. This guide delivers actionable experimental protocols, troubleshooting insights, and a pragmatic translation of recent KR-12 peptide research, empowering microbiology labs to advance antibiotic resistance investigations with confidence.

• Machine Learning Predicts Optimal Ionizable Lipids for mRNA

  2026-05-30

  This study introduces a machine learning-based framework for predicting high-performing ionizable lipids in mRNA lipid nanoparticle (LNP) vaccine formulations, significantly streamlining the optimization process. Experimental validation highlights the superior efficacy of Dlin-MC3-DMA, offering practical insights for nucleic acid delivery research.

• 2,2,2-Trichloroethanol (SKU C6823): Reliable Biochemical for

  2026-05-29

  This article addresses the practical challenges faced by biomedical researchers and lab technicians in cell viability and protein analysis workflows, highlighting how 2,2,2-Trichloroethanol (SKU C6823) provides validated, reproducible solutions. It discusses protocol optimization, data interpretation, and vendor selection, with evidence-backed recommendations for integrating this small molecule biochemical into molecular biology research.

• Sodium Dicloxacillin Monohydrate: Precision, Assay Innovatio

  2026-05-29

  Explore the advanced assay principles and nuanced pharmacology of sodium dicloxacillin monohydrate, a key β-lactam antibiotic for Gram-positive infection research. This article offers unique insights into assay optimization, analytical techniques, and translational relevance for MSSA investigations.

• PPARγ Activation Modulates Macrophage Polarization in IBD vi

  2026-05-28

  This study demonstrates that activating PPARγ can shift macrophage polarization from proinflammatory M1 to anti-inflammatory M2 phenotypes in a murine model of inflammatory bowel disease (IBD), primarily through modulation of the STAT-1/STAT-6 signaling pathways. These findings highlight the therapeutic potential of PPARγ targeting for immunometabolic disease research and provide a mechanistic basis for evaluating selective PPARγ modulators in inflammation.

15147 records 1/1010 page Next 12345 下5页 Last page